OptiNose
🇳🇴Norway
- Country
- 🇳🇴Norway
- Ownership
- Public
- Established
- 2000-01-01
- Employees
- 132
- Market Cap
- $155.3M
- Website
- http://www.optinose.com
- Introduction
OptiNose, Inc. operates as a pharmaceutical company. The firm engages in the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists. Its products include the XHANCE and ONZETRA Xsail. The company was founded by Per Gisle Djupesland and Helena Kyttari Djupesland in October 2000 and is headquartered in Yardley, PA.
Bioavailability Study to Compare OPTINOSE SUMATRIPTAN With IMITREX® in Healthy Subjects
- First Posted Date
- 2012-01-11
- Last Posted Date
- 2012-02-29
- Lead Sponsor
- Optinose US Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT01507610
- Locations
- 🇺🇸
Celerion, Neptune, New Jersey, United States
Safety & Efficacy of a Single Dose of Sumatriptan Powder Delivered Intranasally With the Bi-directional Device in Adults With Acute Migraine
- First Posted Date
- 2011-10-31
- Last Posted Date
- 2015-05-06
- Lead Sponsor
- Optinose US Inc.
- Target Recruit Count
- 223
- Registration Number
- NCT01462812
- Locations
- 🇺🇸
Premiere Research Institute, West Palm Beach, Florida, United States
🇺🇸Headache Wellnes Center, Greensboro, North Carolina, United States
🇺🇸MedVadis, Watertown, Massachusetts, United States
© Copyright 2025. All Rights Reserved by MedPath